What are we paying for? A cost-effectiveness analysis of patented denosumab and generic alendronate for postmenopausal osteoporotic women in Australia
| Main Authors: | , , , |
|---|---|
| Format: | Online |
| Language: | English |
| Published: |
BioMed Central
2016
|
| Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5064794/ |